revance®
REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

INVESTOR FACT SHEET

Issued January 22, 2018

KEY HIGHLIGHTS

January 8, 2018
Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis

January 4, 2018
Revance Provides Update on Clinical Milestones and Financial Outlook for 2018

December 11, 2017
Revance Announces Closing of Public Offering of Common Stock

COMPANY BASICS

Headquarters
Revance Therapeutics, Inc.
7555 Gateway Boulevard
P.O. Box 303
Newark, California 94560-0303
Phone:(510)742-3400

Employees: 131*
Website: www.revance.com

Stock Symbol: RVNC
Stock Exchange: NASDAQ
Market Cap: ~$1.2 billion**

Key Contacts
Investor Relations:
Jeanie Herbert
714-325-3584
jherbert@revance.com

Burns McClellan
Ami Bavishi
212-213-0006
abavishi@burnsmc.com

Trade Media:
Nadine Tosk
(847) 920-9858
nadinepr@gmail.com

General Media:
TOGORUN
Mariann Caprino
(917) 242-1087
mcaprino@togorunl.com

Transfer Agent
Computershare
+1 (877) 373 6374 (US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
For requests by email:
web.queries@computershare.com

ADVANCING A LONG-ACTING, NEXT GENERATION NEUROMODULATOR

ABOUT REVANCE THERAPEUTICS, INC.

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary, stabilizing excipient peptide technology, which when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, musculoskeletal conditions and muscle movement disorders. Current sales of neurotoxins are estimated to be $3.7 billion globally and are expected to grow to $6.6 billion by 2022. The company anticipates that its product candidates will contribute to that growth.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in clinical development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It could be the first differentiated neuromodulator introduced in nearly 30 years and has the potential to provide increased response rates and extended duration.



The company is also developing a topically applied neurotoxin for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical. Beyond botulinum toxin, Revance believes that its proprietary, stabilizing excipient peptide technology has the potential to be applied to a variety of other macromolecules—from over-the-counter beauty products to prescription drugs used daily to treat chronic diseases.

ADVANCING NEUROTOXIN PIPELINE

Botulinum Toxin is a "Pipeline within a Product"





*As of September 30, 2017 **As of January 22, 2018



REVANCE AESTHETICS

Revance is focusing on the largest segment within facial aesthetics, glabellar (frown) lines.



Deep facial muscles that form frown lines are approved for treatment by current injectable botulinum toxins and are estimated to represent a nearly $1 billion global opportunity. These marketed neurotoxins have shown duration of effect of approximately 3-4 months. In the SAKURA 1 and SAKURA 2 Phase 3 pivotal trials, DaxibotulinumtoxinA for Injection (RT002) achieved a 6-month duration of effect. The company plans to complete the SAKURA 3 open-label, long-term safety study in the second half of 2018, and pending FDA approval, launch the product in the U.S. in 2020.

REVANCE THERAPEUTICS

Therapeutic sales of neurotoxins globally were estimated to be $1.8 billion in 2015, larger and faster-growing than aesthetics. Revance plans to build a significant therapeutics portfolio, initially addressing cervical dystonia and plantar fasciitis.

Cervical dystonia is a very painful and debilitating neurologic disorder affecting the neck and shoulder muscles. Treatment for cervical dystonia involves regular neurological intervention. The most commonly prescribed treatment for cervical dystonia is botulinum toxin type A, which can reduce the signs and symptoms of the affliction. In May 2017, the company released positive 24-week results from its Phase 2 dose-escalating trial using RT002 injectable for the treatment of cervical dystonia and was then granted Orphan Drug Designation by the FDA. In the second quarter of 2018, the company plans to initiate a Phase 3 study for the treatment of cervical dystonia.



Plantar fasciitis, the most common cause of heel pain, is triggered by inflammation of the connective tissue in the arch of the foot. The company has initiated a Phase 2a trial using RT002 injectable to reduce the signs and symptoms of plantar fasciitis. The company plans to initiate a second Phase 2a trial in 2018.

DAXIBOTULINUMTOXINA TOPICAL

Revance plans to pursue indications for its DaxibotulinumtoxinA Topical where topical administration of botulinum toxin provides a meaningful advantage over injection. It is designed to provide treatment with no needles, no downtime, no bruising and no pain. The topical drug candidate is in preclinical development as a potential treatment for a number of aesthetic and therapeutic uses.

2018 FINANCIAL OUTLOOK (AS OF JANUARY 4, 2018)

The company had unaudited cash and investments of greater than $280 million at December 31, 2017. Cash burn for 2018 is expected to be in the range of $117-$137 million.

SELL-SIDE COVERAGE

FIRM	ANALYST
Barclays	Doug Tsao
Cantor Fitzgerald	Louise Chen
Cowen and Company	Ken Cacciatore
Guggenheim	Rohit Vanjani
JMP Securities	Don Ellis
Piper Jaffray & Company	David Amsellem
Mizuho	Difei Yang
SunTrust Robinson Humphrey, Inc.	John T. Boris
William Blair	Tim Lugo

BOARD OF DIRECTORS

Angus C. Russell
Chairman of the Board

Dan Browne
Co-Founder, President & CEO

Robert Byrnes
Experienced Medical Device & Biotechnology Executive

Mark Foley
RWI Ventures

Phyllis Gardner, M.D.
Professor of Medicine, Stanford University

Julian Gangolli
GW Pharmaceuticals Inc.

Philip Vickers, Ph.D.
Northern Biologics, Inc.

EXECUTIVE MANAGEMENT TEAM

Dan Browne
Co-Founder, President & CEO

Lauren Silvernail
CFO & Chief Business Officer

Abhay Joshi, Ph.D.
Chief Operating Officer

Todd Zavodnick
Chief Commercial Officer and President, Aesthetics & Therapeutics

Justin Ford
VP, Human Resources and Head of People

FORWARD-LOOKING STATEMENTS

This Investor Fact Sheet contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties are risks described in the "Risk Factors" section of the Form 10-Q filed November 3, 2017. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.